Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C132851> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- NCIT_C132851 IAO_0000115 "A variant of signal regulatory protein alpha (SIRPa) that antagonizes the human cell surface antigen CD47, with potential phagocytosis-inducing, immunostimulating and antineoplastic activities. Upon administration, evorpacept binds to CD47 expressed on tumor cells and prevents the interaction of CD47 with its ligand SIRPa, a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of the pro-phagocytic signal calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor cytotoxic T-lymphocyte (CTL) immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate." @default.
- NCIT_C132851 NCIT_A32 NCIT_C1909 @default.
- NCIT_C132851 NCIT_A7 NCIT_C25795 @default.
- NCIT_C132851 NCIT_NHC0 "C132851" @default.
- NCIT_C132851 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C132851 NCIT_P107 "Evorpacept" @default.
- NCIT_C132851 NCIT_P108 "Evorpacept" @default.
- NCIT_C132851 NCIT_P208 "CL519706" @default.
- NCIT_C132851 NCIT_P210 "2484949-51-9" @default.
- NCIT_C132851 NCIT_P319 "X7K762X1IJ" @default.
- NCIT_C132851 NCIT_P322 "CTRP" @default.
- NCIT_C132851 NCIT_P322 "FDA" @default.
- NCIT_C132851 NCIT_P322 "GDC" @default.
- NCIT_C132851 NCIT_P329 "787529" @default.
- NCIT_C132851 NCIT_P330 "787529" @default.
- NCIT_C132851 NCIT_P375 "CD47 Antagonist ALX148" @default.
- NCIT_C132851 NCIT_P399 "787529" @default.
- NCIT_C132851 normalizedInformationContent "100" @default.
- NCIT_C132851 referenceCount "1" @default.
- NCIT_C132851 hasExactSynonym "ALX 148" @default.
- NCIT_C132851 hasExactSynonym "ALX-148" @default.
- NCIT_C132851 hasExactSynonym "ALX148" @default.
- NCIT_C132851 hasExactSynonym "CD47 Antagonist ALX148" @default.
- NCIT_C132851 hasExactSynonym "CD47/SIRPa-blocking Agent ALX148" @default.
- NCIT_C132851 hasExactSynonym "EVORPACEPT" @default.
- NCIT_C132851 hasExactSynonym "Evorpacept" @default.
- NCIT_C132851 hasExactSynonym "LGGL-ALX-148" @default.
- NCIT_C132851 hasExactSynonym "SIRPa Variant ALX148" @default.
- NCIT_C132851 inSubset NCIT_C116977 @default.
- NCIT_C132851 inSubset NCIT_C116978 @default.
- NCIT_C132851 inSubset NCIT_C128784 @default.
- NCIT_C132851 inSubset NCIT_C157711 @default.
- NCIT_C132851 inSubset NCIT_C157712 @default.
- NCIT_C132851 inSubset NCIT_C176424 @default.
- NCIT_C132851 inSubset NCIT_C177537 @default.
- NCIT_C132851 inSubset NCIT_C63923 @default.
- NCIT_C132851 type Class @default.
- NCIT_C132851 isDefinedBy ncit.owl @default.
- NCIT_C132851 label "Evorpacept" @default.
- NCIT_C132851 subClassOf NCIT_C129824 @default.
- NCIT_C132851 subClassOf NCIT_C132851 @default.
- NCIT_C132851 subClassOf NCIT_C163758 @default.
- NCIT_C132851 subClassOf NCIT_C1908 @default.
- NCIT_C132851 subClassOf NCIT_C1909 @default.
- NCIT_C132851 subClassOf NCIT_C192655 @default.
- NCIT_C132851 subClassOf NCIT_C2189 @default.
- NCIT_C132851 subClassOf NCIT_C274 @default.